NYSEAMERICAN:PLX - Protalix Biotherapeutics Stock Price, Price Target & More

Protalix Biotherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PLX."

Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) released its quarterly earnings data on Wednesday, May, 9th. The company reported ($0.06) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.09) by $0.03. The firm earned $4.55 million during the quarter, compared to analyst estimates of $4.40 million. During the same period last year, the business earned ($0.48) EPS. View Protalix Biotherapeutics' Earnings History.

1 equities research analysts have issued 12 month price targets for Protalix Biotherapeutics' shares. Their forecasts range from $5.00 to $5.00. On average, they anticipate Protalix Biotherapeutics' share price to reach $5.00 in the next year. View Analyst Ratings for Protalix Biotherapeutics.

Protalix Biotherapeutics saw a drop in short interest in May. As of May 31st, there was short interest totalling 5,081,891 shares, a drop of 3.1% from the May 15th total of 5,242,949 shares. Based on an average trading volume of 416,075 shares, the short-interest ratio is presently 12.2 days. Approximately 3.7% of the company's shares are sold short.

Some companies that are related to Protalix Biotherapeutics include Biotest (BIO), ProMetic Life Sciences (PLI), Genfit (GNFTF), Mesoblast (MSB), Theratechnologies (TH), Mesoblast (MEOBF), Emerald Health Therapeutics (EMH), Starpharma (SPL), MediGene (MDG1), Oxford BioMedica (OXB), BioTime (BTX), Resverlogix (RVX), 22nd Century Group (XXII), Neptune Technologies & Bioressources (NEPT) and Monash IVF Group (MVF).

Media headlines about PLX stock have been trending somewhat positive recently, according to Accern Sentiment. The research firm identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Protalix Biotherapeutics earned a news impact score of 0.08 on Accern's scale. They also assigned headlines about the company an impact score of 47.03 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Protalix Biotherapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Opaleye Management Inc. (2.24%) and SG Americas Securities LLC (0.15%). Company insiders that own Protalix Biotherapeutics stock include Camber Capital Management Llc, Madalena Energy Inc, Moshe Manor, Randall Peel Boyd, Steve Dabner and Terence Stanley Meek. View Institutional Ownership Trends for Protalix Biotherapeutics.

PLX stock was purchased by a variety of institutional investors in the last quarter, including Opaleye Management Inc. and SG Americas Securities LLC. Company insiders that have bought Protalix Biotherapeutics stock in the last two years include Moshe Manor, Randall Peel Boyd, Steve Dabner and Terence Stanley Meek. View Insider Buying and Selling for Protalix Biotherapeutics.

Shares of PLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PLX stock can currently be purchased for approximately $0.44.

Protalix Biotherapeutics has a market capitalization of $308.37 million.

Protalix Biotherapeutics' mailing address is 2 Snunit St, Science Park, Pob 455, KARMIEL, 20100, Israel. The company can be reached via phone at +972-4-9028100.